-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $980

Benzinga·11/02/2026 12:33:02
Diffusion vocale
Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $795 to $980.